Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Parotid Gland Clear all
Completed Phase 3 Interventional Results available

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT02610868
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765
View directory record Official record
Conditions
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Interventions
AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo, AAV2-hAQP1 Concentration 3, AAV2-hAQP1 Concentration 4
Genetic · Other
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

NCT06544798
View directory record Official record
Conditions
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Interventions
AAV2-hAQP1
Genetic
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Gilbert, Arizona • Miami, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 27, 2026, 5:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salivary Evaluation in Healthy Volunteers

NCT00001390
View directory record Official record
Conditions
Healthy, Salivary Gland Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 27, 2026, 5:23 PM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 27, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment

NCT00409331
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Amifostine, Intensity- Modulated Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx

NCT03418792
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Xerostomia Due to Radiotherapy
Interventions
Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia

NCT04043104
View directory record Official record
Conditions
Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer
Interventions
AAV2hAQP1: 1 x 10^11 vg/gland (single gland), AAV2hAQP1: 3 x 10^10 vg/gland (both glands), AAV2hAQP1: 3 x 10^11 vg/gland (single gland), AAV2hAQP1: 1 x 10^11 vg/gland (both glands), AAV2hAQP1: 1 x 10^12 vg/gland (single gland), AAV2hAQP1: 3 x 10^11 vg/gland (both glands), AAV2hAQP1: 3 x 10^12 vg/gland (single gland), AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
Drug
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Stanford, California • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 27, 2026, 5:23 PM EDT
Recruiting Not applicable Interventional

Impact of Photobiomodulation (PBM) on Biomarkers of Radiation Lymphedema and Fibrosis in Head and Neck Cancer Patients

NCT06708754
View directory record Official record
Conditions
Radiation Lymphedema, Radiation Fibrosis, Head and Neck Cancer
Interventions
Photobiomodulation (PBM) Therapy, Sham PBM
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

NCT00515437
View directory record Official record
Conditions
Drooling
Interventions
Botulinum Toxin Type B (Myobloc), Matched placebo to Myobloc
Biological
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Scottsdale, Arizona • Northridge, California • Oxnard, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer

NCT01576939
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer

NCT01663246
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Saliva Sample
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

NCT00405405
View directory record Official record
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

DryShield vs Cotton Roll Isolation During Sealants Placement: Efficiency and Patient Preference

NCT02995369
View directory record Official record
Conditions
Time, Patient Preference
Interventions
DryShield, Cotton rolls
Device · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 14 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

NCT00372320
View directory record Official record
Conditions
Parotid Salivary Dysfunction
Interventions
Gene Transfer, AdhAQP1
Genetic · Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 27, 2026, 5:23 PM EDT
Completed No phase listed Observational

Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation

NCT00001523
View directory record Official record
Conditions
Radiation Injuries, Xerostomia
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Trial of Parotid Sparing Whole Brain Radiation

NCT03595878
View directory record Official record
Conditions
Xerostomia
Interventions
Parotid sparing WBRT, Standard WBRT
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Identification of Nerves Using Fluorescein Sodium

NCT06054178
View directory record Official record
Conditions
Pleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck, Thyroid Disease, Thyroidectomy
Interventions
Fluorescein Sodium
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Cocaine in Parotid Saliva, Blood and Urine - 4

NCT00000190
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Parotid Gland
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1992
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 27, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia

NCT07278557
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
MRI sialography, Parotid Duct Sparing Radiation Therapy Planning, Parotid Sparing Radiation Therapy Planning
Device · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

NCT05060341
View directory record Official record
Conditions
Radiation-induced Xerostomia
Interventions
Not listed
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
18 Years to 81 Years
Enrollment
22 participants
Timeline
2020 – 2027
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 27, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770
View directory record Official record
Conditions
Sjögren's Syndrome, Xerostomia
Interventions
Dexamethasone Parotid Irrigation, Placebo Parotid Irrigation
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 27, 2026, 5:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Stromal Vascular Fraction for Treatment of Xerostomia

NCT03061110
View directory record Official record
Conditions
Xerostomia Due to Radiotherapy (Disorder)
Interventions
Stromal Vascular Fraction, Usual Care
Biological · Other
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132
View directory record Official record
Conditions
Sialorrhea
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 27, 2026, 5:23 PM EDT